Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 6/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL486028 | 0.83 | F2R (0.56) | F2RMAOA | |
| SCHEMBL486000 | 0.74 | HPGD (0.42) | F2RMC4R | |
| SCHEMBL13191659 | 0.73 | F2R (0.43) | F2R | |
| SCHEMBL485716 | 0.73 | MEN1 (0.51) | F2RKCNH2 | |
| SCHEMBL485729 | 0.71 | F2R (0.61) | F2R | |
| SCHEMBL486001 | 0.70 | SMN1; SMN2 (0.50) | — | |
| SCHEMBL8272741 | 0.70 | RPS6KB1 (0.43) | MAOA | |
| SCHEMBL5294375 | 0.70 | RPS6KB1 (0.43) | MAOA | |
| SCHEMBL27687082 | 0.70 | KDM1A (0.45) | CYP3A4CYP2C19MAOA | |
| SCHEMBL17450394 | 0.70 | NPC1 (0.55) | DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411363-B1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | BAYER IP GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20150183773-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
| US-8987248-B2 | Substituted piperidines as Par-1 antagonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2411363-A1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | Bayer Pharma AG (DE) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010108608-A1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183773-A1 | Substituted piperidines | VHL, PIR, PIGO | F2R 1243/4885DRD4 722/4885SLC6A5 3968/4885 |
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | F2R, F2RL1, F2RL3 | F2R 1/4885DRD4 1141/4885SLC6A5 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.